



November 11,2022

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended September 30, 2022

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (started at 6:25 p.m. and concluded at 7:15 p.m.), the Unaudited Financial Results for the quarter ended September 30, 2022 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2022;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2022 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Shah
Company Secretary

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8th Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2022

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)
		Three months ended 30th September 2022	Preceding Three months ended 30th June 2022	Corresponding Three months ended 30th September 2021	Year ended 30th June 2022
		Unaudited	Audited [Refer note 4]	Unaudited	Audited
1.	Revenue from Operations	29,755.0	29,589.0	27,280.0	111,441.0
2.	Other Income	342.0	310.0	304.0	1,319.0
3.	Total income (1+2)	30,097.0	29,899.0	27,584.0	112,760.0
4.	Expenses				
	a) Cost of materials consumed	8,022.0	7,247.0	8,384.0	32,372.0
	b) Purchases of stock-in-trade	516.0	499.0	651.0	2,083.0
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	111.0	1,114.0	(1,045.0)	(475.0)
	d) Employee benefits expense	4,278.0	4,213.0	3,974.0	16,756.0
	e) Depreciation and amortisation expense	748.0	747.0	690.0	2,708.0
	f) Impairment	-	73.0	-	73.0
	g) Finance Costs	16.0	2.0	14.0	42.0
	h) Other expenses	7,746.0	10,539.0	7,509.0	33,864.0
	Total expenses (4)	21,437.0	24,434.0	20,177.0	87,423.0
5.	Profit before exceptional items and tax (3-4)	8,660.0	5,465.0	7,407.0	25,337.0
6.	Less: Exceptional items	-	-	-	-
7.	Profit before tax (5-6)	8,660.0	5,465.0	7,407.0	25,337.0
8.	Tax expenses				
	Current Tax	2,191.0	1,233.0	1,930.0	6,502.0
	Deferred Tax	103.0	113.0	(60.0)	4.0
	Tax for earlier years	-	-	-	(421.0)
9.	Net Profit for the period/ year (7-8)	6,366.0	4,119.0	5,537.0	19,252.0
10.	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	i. Re-measurement gains/(losses) on defined benefit plans	23.0	324.0	(22.0)	94.0
	ii. Income tax effect	(6.0)	(82.0)	6.0	(24.0)
	Total Other Comprehensive Income, net of tax	17.0	242.0	(16.0)	70.0
11.	Total Comprehensive Income for the period/year (9+10)	6,383.0	4,361.0	5,521.0	19,322.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	59,989.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)				
	(a) Basic and Diluted (in Rs.)	* 38.3	* 24.8	* 33.4	116

Notes:

- The above results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on November 11, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
- Previous period figures have been regrouped/ reclassified wherever necessary. The figures for the preceding 3 months ended 30th June, 2022 are the balancing figures between the audited figures in respect of the full financial year ended 30th June 2022 and the year to date figures upto the third quarter of that financial year.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited.

Milind Vasant
Thatte

Digitally signed by Milind
Vasant Thatte
Date: 2022.11.11
19:17:24 +05'30'

Milind Thatte
Managing Director

Place : Mumbai

Date : 11 November 2022

Please visit us at our website www.pghealthindia.com



Procter & Gamble Health Announces First Quarter results

Sales up by 9% and Profit after tax up by 15% for quarter ended September 30, 2022

Mumbai, November 11, 2022: Procter & Gamble Health Limited announced today its financial results for the quarter ended September 30, 2022. The company has recorded a strong performance with sales of ₹ 292 crores, up 9% vs a year ago behind strong off-take on key brands supported by extensive consumer awareness and HCP engagement efforts. The Profit After Tax (PAT) was ₹ 63.7 crores, up by 15 % vs a year ago backed by improved product mix and productivity initiatives.

Mr. Milind Thatte, Managing Director, P&G Health India, said, *“We have delivered a very productive quarter with strong profit growth over last quarter, as well as over last year. For the first time ever, our domestic sales for India, for the month of September, crossed ₹100crores. This is a testament to the quality of our trusted brands and superiority in execution. Our teams have showcased outstanding efforts to meet the requirements of our customers and consumers by strengthening our go-to-market strategy and visibility programs; expanding distribution and pharmacy outreach; and maximising presence across e-commerce platforms. All while combining breakthrough science with deep consumer and patient understanding to deliver healthcare with humancare. The quarter saw focussed efforts on condition awareness across our therapy areas through extensive nation-wide scientific engagement programs. These included round table discussions, participation at key medical conferences, screening camps and our 1st ‘Phygital Nerve Care Forum Express’ which had 17 Neuropathy KOLs from 12 cities engaging with 3700 HCPs on key neuropathy topics.*

‘Under SEHAT, our flagship CSR program, the Company’s employees joined the nation in celebrating ‘Daan Utsav’ (Joy of Giving Week) with our annual ‘Post & Give Challenge’. For the 3rd consecutive year, employees across the country come together to participate in different acts of giving, and for every act posted on our internal employee connect platform, the Company donated to HelpAge India’s community outreach initiative that supports healthcare needs of disadvantaged elderly. The quarter also saw a new batch of P&G Health Scholars graduate from PHFI’s Indian Institutes of Public Health. The P&G Health Scholarship Program in partnership with the Public Health Foundation of India (PHFI) supports deserving students seeking to pursue master’s in public health and is our joint endeavour to help build a public health cadre to address India’s existing and emerging public health challenges.”

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pq.com

Registered Office :

Procter & Gamble Health Limited
 CIN: L99999MH1967PLC013726
 Godrej One, 8th Floor, Pirojshanagar,
 Eastern Express Highway, Vikhroli East,
 Mumbai 400 079 | Tel: (91-22) 6866 9000

Site Address:

Procter & Gamble Health Limited
 CIN: L99999MH1967PLC013726
 Usgaon, Ponda Taluka,
 Goa 403 407 | Tel: (91-832) 2347105
www.pghealthindia.com

Independent Auditor's Review Report on quarterly Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended September 30, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048


Sumant Sakhardande

Partner

Membership No.: 034828

UDIN: 22034828BCWKI07058



Mumbai

November 11, 2022